![](https://i.imgur.com/CLvY2jA.png")
It consists of weakened viruses that are put in the nose - where the real viruses enter the body.
Berlin researchers have taken an important step in the development of a live vaccine: In animal experiments, this provides better protection against Covid-19 than previous vaccines.
Such live vaccines are also used against other diseases, such as measles or polio . However, the development and production is far more complex than, for example, the production of mRNA.
So far, live vaccines have been created by allowing natural viruses to mutate under certain conditions in the laboratory over many years. In contrast, sCPD9 is a virus variant in which the researchers deliberately inserted 200 mutations.
This is possible because we now have a much better understanding of the individual functions of the virus genes.
The US company Codagenix is further developing a similar vaccine. It has already started clinical trials.
The weakened virus can attack human mucous membrane cells, but hardly multiplies there. "For this reason, you can vaccinate with virus doses that are many times higher than those that occur with natural infections," explains Emanuel Wyler from the Max Delbrück Center, who was involved in the work. This could lead to a stronger and more reliable immune response than a normal infection.
https://www.welt.de/wissenschaft/article...spray.html
Berlin researchers have taken an important step in the development of a live vaccine: In animal experiments, this provides better protection against Covid-19 than previous vaccines.
Such live vaccines are also used against other diseases, such as measles or polio . However, the development and production is far more complex than, for example, the production of mRNA.
So far, live vaccines have been created by allowing natural viruses to mutate under certain conditions in the laboratory over many years. In contrast, sCPD9 is a virus variant in which the researchers deliberately inserted 200 mutations.
This is possible because we now have a much better understanding of the individual functions of the virus genes.
The US company Codagenix is further developing a similar vaccine. It has already started clinical trials.
The weakened virus can attack human mucous membrane cells, but hardly multiplies there. "For this reason, you can vaccinate with virus doses that are many times higher than those that occur with natural infections," explains Emanuel Wyler from the Max Delbrück Center, who was involved in the work. This could lead to a stronger and more reliable immune response than a normal infection.
https://www.welt.de/wissenschaft/article...spray.html
